According to the latest research by Future Market Insights, the glucagon injectable market is set to experience 5.4% growth during the year 2021-2031. Glucagon is a hormone that mobilizes the glucose in the blood circulation, through the breakdown of glycogen to glucose. Deficiency of this hormone causes a condition called hypoglycaemia.
To treat hypoglycaemia, glycogen injections and tablets are given to the patients. Glycogen injections are used for the treatment of severe hypoglycaemia and diagnostics purposes. In diagnostics, it is used for radiographic examination of the small bowel, duodenum, colon and stomach when diminished intestinal motility would be advantageous. The glucagon injectable market is mainly driven by an increase in the prevalence of type 1 and type 2 diabetes, new product launches and hypoglycaemia unawareness.
What is the Driving Demand for Glucagon Injectable?
Glucagon injections are used to treat severe hypoglycaemia and for diagnostics purposes. The growth of this market is anticipated due to the rise in prevalence of diabetes, unawareness about hypoglycaemia and new product launches by the market players.
According to the International Diabetes Federation report, by 2045, globally there will be 700 million people between 20-79 years who will be suffering from diabetes. On average a person having type 1 diabetes suffers at least 2-3 episodes of hypoglycaemia in a week. This acts as a driver for the glucagon injectable markets. Sometimes people having blood sugar levels below 70 mg/dL and do not experience any symptoms.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-14042
This is called hypoglycaemia unawareness and these people are at a higher risk of any severe hypoglycaemia episode. According to a study conducted by the HAT Brazil study group 20.6% and 10.6% of people with type 1 and type 2 diabetes respectively showed asymptomatic hypoglycaemia. This acts as a driver for the market. The companies are investing in the research and development of glucagon injectable and for their approval. For instance, in December 2020, FDA approved the first generic glucagon injection for the treatment of hypoglycaemia and diagnostics aid.
Impact of COVID on Glucagon Injectable Market
The COVID-19 has impacted the glucagon injectable market. Due to the pandemic, the research and development were mainly carried out in the field of COVID. Due to this shift, the research of glucagon injectables was affected.
Also, with the change in lifestyle and eating habits, the prevalence of diabetes has increased. Therefore, putting people at a higher risk of diabetes and hypoglycaemia. Hence, COVID-19 had both positive and negative impacts on the glucagon injectable market.
Who are the Key Manufacturers and Suppliers of Glucagon Injectable?
The manufacturers and suppliers of glucagon injectables are
- Fresenius SE & Co. KGaA
- Xeris Pharmaceuticals Inc
- Novo Nordisk A/S
- Amphastar Pharmaceuticals Inc.
- Lilly USA
- LLC. Zealand Pharma A/S.
- Avalon Pharma Pvt. Ltd
For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14042
Why Future Market Insights?
• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com